Japan Dengue Vaccines Market Size, Share, and COVID-19 Impact Analysis, By Type (Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, and Others), By Application (Hospitals, Clinics, Research Institutes, and Others), and Japan Dengue Vaccines Market Insights, Industry Trend, Forecasts to 2033.

Japan Dengue Vaccines Market Insights Forecasts to 2033

• The Japan Dengue Vaccines Market Size was valued at USD 29.6 Million in 2023
• The Market Size is Growing at a CAGR of 11.36% from 2023 to 2033
• The Japan Dengue Vaccines Market Size is Expected to Reach USD 86.8 Million by 2033

The Japan Dengue Vaccines Market Size is Anticipated to Reach USD 86.8 Million by 2033, growing at a CAGR of 11.36% from 2023 to 2033.

Market Overview

The Japan dengue vaccines market refers to the industry focused on the development, production, and distribution of vaccines designed to prevent dengue fever in Japan. Increasing government and non-governmental organization financing and support in Japan for dengue vaccine development and distribution is another important growth factor for the Japan dengue vaccine market. Public-private collaborations in Japan and expanded healthcare resources are being implemented to accelerate vaccine availability in dengue-endemic areas within the country. Additionally, biotechnology advancements in Japan, especially in immunology and genetic engineering, have played a vital role in market expansion. Technological progress in Japan’s pharmaceutical sector has enabled the creation of safer and more effective vaccine alternatives, such as recombinant vaccines, which activate the immune system by using genetically engineered viruses.

Report Coverage

This research report categorizes the market for the Japan dengue vaccines based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan dengue vaccines market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan dengue vaccines market.

Driving Factors

The concerning increase in dengue cases in Japan and throughout the world is one of the main drivers of the Japan dengue vaccine market's growth. Because of this rising incidence in Japan, creating and implementing efficient vaccinations is a top public health concern. Further increasing the need for extensive vaccination campaigns and cutting-edge vaccine research in Japan is the fact that climate change has increased the geographic range of the Aedes mosquito, which spreads the dengue virus in Japan. The market for dengue vaccines in Japan is expanding significantly due to rising production capacity and research and development initiatives by large pharmaceutical companies. One of the biggest pharmaceutical companies in Japan, Takeda, is aggressively growing its dengue vaccine manufacturing. Approval of the shot in the United States has been requested by Takeda, the biggest pharmaceutical company in Japan. Takeda wants to produce 100 million doses of the dengue vaccine annually and make up to $2 billion in sales globally.

Restraining Factors

The possibility of vaccine reluctance and disinformation is one significant obstacle. Negative media coverage and false information can affect how the public views the safety and effectiveness of vaccines. Public health officials must fund educational initiatives that offer factual and scientifically supported information regarding dengue vaccinations in order to address this.

Market Segmentation

The Japan dengue vaccines market share is classified into types and application.

• The attenuated vaccines segment is expected to hold a significant market share through the forecast period.

The Japan dengue vaccines market is segmented by types into attenuated vaccines, inactivated vaccines, recombinant vaccines, and others. Among these, the attenuated vaccines segment is expected to hold a significant market share through the forecast period. One of the most researched and used vaccines is live attenuated, which uses a weakened virus to elicit an immune response. The long-lasting immunity and efficacy of these vaccinations in preventing dengue fever are well-known.

• The hospitals segment is expected to hold a significant market share through the forecast period.

The Japan dengue vaccines market is segmented by application into hospitals, clinics, research institutes, and others. Among these, the hospitals segment is expected to hold a significant market share through the forecast period. Hospitals are the main end users because of their responsibility for addressing dengue-related problems and delivering vaccinations to sizable populations. Hospitals are an important part of the dengue vaccination ecosystem because they have the infrastructure and medical know-how to manage the logistics of vaccine administration, storage, and follow-up care.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan dengue vaccines market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sanofi Pasteur
• Takeda Pharmaceutical Company Limited
• Butantan Institute
• Biological E. Limited
• Merck & Co.
• Bharat Biotech International Limited
• Panacea Biotec Limited
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Japan Dengue Vaccines Market based on the below-mentioned segments:

Japan Dengue Vaccines Market, By Type

• Attenuated Vaccines
• Inactivated Vaccines
• Recombinant Vaccines
• Others

Japan Dengue Vaccines Market, By Application

• Hospitals
• Clinics
• Research Institutes
• Others